Who owns Vir Biotechnology, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of VIR from SEC Form 13F filings across 238 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 238 institutions disclosed 146.6M shares of Vir Biotechnology, Inc. worth $1.49B — about 87.4% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
238
13F holders
$1.49B
value, 2026 filers
87.4%
of shares outstanding (146.6M sh)
32
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of VIR's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 20.7M | $210.7M | 0.0% | 12.3% | +14.9% |
| 2 | ARCH Venture Management, LLC | 12.7M | $129.4M | 11.8% | 7.6% | -1.7% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11.5M | $117.1M | 0.0% | 6.9% | +24.7% |
| 4 | SB INVESTMENT ADVISERS (UK) LTD | 10.9M | $111.6M | 1.5% | 6.5% | 0.0% |
| 5 | STATE STREET CORP | 10.0M | $101.5M | 0.0% | 5.9% | +39.5% |
| 6 | GSK plc | 8.6M | $87.1M | 14.5% | 5.1% | 0.0% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 6.4M | $65.1M | 0.0% | 3.8% | +18.7% |
| 8 | Point72 Asset Management, L.P. | 5.7M | $57.7M | 0.1% | 3.4% | +190.3% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 3.3M | $34.1M | 0.0% | 2% | +26.0% |
| 10 | DIMENSIONAL FUND ADVISORS LP | 3.1M | $31.8M | 0.0% | 1.9% | +20.9% |
| 11 | ADAR1 Capital Management, LLC | 2.5M | $25.0M | 1.1% | 1.5% | -10.5% |
| 12 | GOLDMAN SACHS GROUP INC | 2.4M | $24.1M | 0.0% | 1.4% | -27.2% |
| 13 | FMR LLC | 2.3M | $23.6M | 0.0% | 1.4% | +11.9% |
| 14 | MORGAN STANLEY | 2.2M | $22.5M | 0.0% | 1.3% | -22.5% |
| 15 | Nuveen, LLC | 2.0M | $20.2M | 0.0% | 1.2% | +94.6% |
| 16 | Pictet Asset Management Holding SA | 2.0M | $19.9M | 0.0% | 1.2% | +31.9% |
| 17 | Boxer Capital Management, LLC | 1.9M | $19.0M | 1.4% | 1.1% | 0.0% |
| 18 | NORTHERN TRUST CORP | 1.4M | $14.6M | 0.0% | 0.9% | +45.3% |
| 19 | Hudson Bay Capital Management LP | 1.4M | $13.9M | 0.0% | 0.8% | -7.2% |
| 20 | GordonMD Global Investments LP | 1.4M | $13.8M | 6.7% | 0.8% | -10.9% |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.3M | $13.5M | 0.0% | 0.8% | +12.9% |
| 22 | BANK OF AMERICA CORP /DE/ | 1.1M | $11.6M | 0.0% | 0.7% | +18.3% |
| 23 | TWO SIGMA INVESTMENTS, LP | 1.1M | $11.3M | 0.0% | 0.7% | -22.9% |
| 24 | Sio Capital Management, LLC | 1.1M | $11.0M | 1.8% | 0.6% | -28.2% |
| 25 | Savvy Advisors, Inc.NEW | 1.0M | $10.6M | 0.2% | 0.6% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.